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Retinoic Acid (RA) treatment of SH-SY5Y neuroblastoma cells results in activation of phosphatidyl-inositol-3-kinase (PI3K) signalling pathway, and this activation is required for 
RA-induced differentiation. RA activates PI3K and ERK1/2 MAP Kinase signalling pathways through a rapid, non-genomic mechanism that does not require new gene 
transcription or newly synthesized proteins. Activation of PI3K by RA appears to involve the classical nuclear receptor RAR, on the basis of the pharmacological profile of the 
activation, loss and gain of function experiments with MEF-RAR(αβγ)L-/L- null cells, and the physical association between liganded RAR and PI3K kinase activity. Ligand binding 
differentially regulated the association of RAR with the two subunits of PI3K. Immunoprecipitation experiments performed in SH-SY5Y cells showed stable association between 
RARα and p85, the regulatory subunit of PI3K, independently of the presence of RA. In contrast, ligand administration increased the association of p110, the catalytic subunit 
of PI3K, to this complex. The intracellular localization of RAR resulted to be relevant for PI3K activation. A chimerical RAR receptor fusing c-Src myristylation domain to the N-
terminal of RARα (Myr-RARα) was targeted to plasma membrane. Transfection of Myr-RARα to MEF-RAR(αβγ)L-/L-  null cells and COS-7 cells results in strong activation of PI3K 
signalling pathway, although both in the absence as well in the presence of RA. Our results suggest a mechanism in which ligand binding to RAR would play a major role in the 
assembly and intracellular location of a signalling complex involving RAR and the subunits of PI3K. 
Next we have investigated the consequences of the activation of signalling pathways by RA in neuroblastoma cells. Downstream targets of the PI3K/Akt signalling pathway, 
like mTOR or p70S6K, are activated upon RA addition. In addition we show that RA addition rapidly increased phosphorylation of several Akt kinase target proteins in the 
nucleus, identified by an antibody recognizing the phosphorylated Akt motif. We have analyzed possible nuclear protein targets for RA-induced phosphorylation, with the aim 
of finding functional links between non-genomic actions and classical transcriptional actions mediated by RAR. We have found that RA treatment rapidly results in 
phosphorylation of chromatin proteins (core histone H3), as well as proteins involved in transcriptional activation (transcription factor CREB). In a second approach, nuclear 
phospho-proteins from control and RA-treated neuroblastoma cells were purified by affinity chromatography and analysed by 2D-electrophoresis. The differentially expressed 
spots were identified by Mass Spectrometry. We have found that RA treatment induces phosphorylation of chromatin proteins (HMGB1 and Histone H1.5) and proteins involved 
in the processing and transport of mRNA (PABP, hnRNP-K, hnRNP-C1/C2, Nucleophosmin). 
The experiment shown in Fig. 1I argues for a physical interaction between RAR and the subunits of 
PI3K. A stable association between RARα and the regulatory subunit of PI3K, p85, which was not 
affected by the administration of RA, could be detected in SH-SY5Y neuroblastoma cells by 
immunoprecipitation (Fig. 2A and 2B). That complex could be immunoprecipitated from nuclear 
extracts (Fig. 2C). However, association of the catalytic subunit p110-PI3K to that complex  
depends on the administration of RA (Fig. 2A and Fig. 2D), suggesting that activation of RARα by 
its cognate ligand results in the formation of a signalling complex including RARα, and the 
regulatory and catalytic subunits of PI3K. The interaction between RARα and p85-PI3K does not 
appear to be direct, since a protein-protein interaction could not be detected in vitro by GST-
pulldown experiments (Fig. 2E). In the same conditions, the experiment readily detected the 
interaction between RARα and its dimerisation partner RXRα. Consistently with that, binary 
complexes including RARα and p85-PI3K could not be detected when co-expressed in COS-7 cells 
(Fig. 2F). The experiment suggests that other yet unknown proteins mediating or stabilizing the 
interactions between RAR and p85-PI3K might be part of the signalling complex.  
Activation of PI3K/Akt signalling by RA in SH-SY5Y neuroblastoma cells is rapid (within 5 min. 
of treatment) (Fig. 1A), and did not required newly synthesized proteins or newly transcribed 
genes (Fig. 1B). This suggests that activation of PI3K/Akt by RA occurs through an atypical 
non-genomic mechanism. Involvement of the Nuclear Receptor RAR in the activation of 
PI3K/Akt is supported by three types of evidences: 1. The pharmacological specificity of the 
activation, because all RAR agonists tested are good activators of PI3K/Akt (Fig. 1C).  
Surprisingly, RA transcriptional antagonist AGN193109 did not prevented activation of PI3K by 
RA or TTNPB (Fig. 1D), and acts as an agonist activating PI3K/Akt. However, AGN193109 
avoided RA-induced transcriptional activation of RARB (Fig.1E), suggesting a mixed 
agonist/antagonist profile for AGN193109. 2. Loss and gain of function experiments with MEF-
RAR(αβγ)L-/L- cells. RAR null cells have lost the ability of activating PI3K/Akt signalling (Fig. 1G), 
as compared with MEF-wt cells (Fig. 1F). Activation of PI3K/Akt by RA could be restored by 
expressing a functional RARα (Fig. 1H). 3. PI3K activity is associated to liganded RAR in SH-
SY5Y cells, as shown in PI3K assays performed on RARα immunoprecipitates (Fig. 1 I).  
1. Rapid Activation of PI3K/AKT by RA through a 
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The fact that a Nuclear Receptor as RAR is 
involved in signalling actions normally initiated 
at plasma membrane results a paradox and 
deserves to be analyzed. A chimerical receptor 
was produced by fusing c-Src myristylation 
signal to the N-terminal end of RARα.  
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This Myr-RARα is mainly located in the nucleus, but could be detected in the plasma 
membrane at significative levels (Fig. 3A). Moreover, Myr-RARα was present in the lipid rafts 
fractions, plasma membrane microdomains involved in signalling (Fig. 3B). Transfection of 
Myr-RARα chimerical receptor to MEF-RAR(αβγ)L-/L- or COS-7 cells resulted in strong 
activation of PI3K/Akt, that nevertheless could be detected in the absence of RA (Fig. 3C and 
3D). The experiment underscores a novel role for RAR at the membrane, and suggests a 
requirement of the ligand for the location of RAR at the plasma membrane, that could be 
overcome by ectopically targeting of the receptor to the membrane. We have examined the 
intracellular location of RAR. Attempts to show the presence of RAR in plasma membrane 
from SH-SY5Y or NIH-3T3 cells by immunofluorescent confocal microscopy with a variety of 
commercially available anti-RAR antibodies failed (data not shown). Experiments with a 
fluorescent GFP-RARα fusion protein did not show a consistent membrane distribution 
pattern (data not shown). In conventional biochemical cell fractionation experiments 
performed in SH-SY5Y cells RARα could not be detected in microsomal or purified plasma 
membrane fractions by western blot immunodetection (data not shown). Similar fractionation 
experiments were performed in NIH-3T3 cells. As expected, most of the RARγ receptor was 
detected in the nuclear fraction. Administration of RA to NIH-3T3 cells resulted in a strong 
increase in the levels of RARγ into the membrane fractions (microsomal and purified plasma 
membranes), suggesting the idea of a ligand-induced translocation of the receptor to plasma 
membrane (Fig. 3E).  
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Short-time RA treatment of neuroblastoma cells leads to rapid phosphorylation of PI3K/Akt 
downstream substrates, as mTOR and p70S6 kinases (Fig. 4A). The phosphorylation levels of other 
likely targets for that signalling pathway, as transcription factor CREB (Fig. 4B) and Histone H3 
(Fig. 4C) are also increased by RA administration. RA-induced phosphorylation of several nuclear 
Akt substrates was detected in 1D- (Fig. 4D) and 2D- Western Blots (Fig. 4E) with specific 
antibodies against phosphorylated Akt kinase motif. To identify the targets of RA-induced 
phosphorylation in the nucleus, we have set a proteomic approach (Fig. 4F), combining affinity 
purification of phosphoproteins, 2D-electrophoretic separation, and mass spectrometry analysis of 
the differential spots. This approach leaded to the identification of 6 nuclear proteins: 
Nucleophosmin, Histone H1.5, HMGB1, hnRNP-C1/C2, hnRNP-K, and PABP2 (Fig. 4G and 4L). 
Validation of those identified targets is being carried out by their shift towards acidic pI on 2D-
Western blots (Fig. 4H-K) and by immunoprecipitation with antibodies against phosphorylated 
amino acids (Fig. 4M and 4N). These results suggest that RA-induced rapid phosphorylation may 
be involved in chromatin remodelling and mRNA processing, transport and/or translation.  
MW 
hnRNP-K 
hnRNP-C1/C2 HMGB1 
Histone H1.5 
